CD274 and neoplasm: In exploratory analyses, the benefits of OS and ORR were observed with Ipi+Nivo compared to sunitinib among intermediate- and poor-risk patients across tumor PD-L1 expression levels, although the magnitude of benefit was higher in patients that were PD-L1 positive (≥1%).